Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Working Capital Changes (2016 - 2025)

United Therapeutics (UTHR) has disclosed Other Working Capital Changes for 17 consecutive years, with $98.2 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 463.7% to $98.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.9 million through Dec 2025, up 1051.76% year-over-year, with the annual reading at $80.9 million for FY2025, 1051.76% up from the prior year.
  • Other Working Capital Changes hit $98.2 million in Q4 2025 for United Therapeutics, up from -$67.2 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $184.4 million in Q2 2025 to a low of -$134.5 million in Q1 2025.
  • Historically, Other Working Capital Changes has averaged $17.7 million across 5 years, with a median of $7.2 million in 2021.
  • Biggest five-year swings in Other Working Capital Changes: surged 648.41% in 2022 and later plummeted 1086.05% in 2024.
  • Year by year, Other Working Capital Changes stood at $12.6 million in 2021, then soared by 648.41% to $94.3 million in 2022, then crashed by 124.5% to -$23.1 million in 2023, then decreased by 16.88% to -$27.0 million in 2024, then surged by 463.7% to $98.2 million in 2025.
  • Business Quant data shows Other Working Capital Changes for UTHR at $98.2 million in Q4 2025, -$67.2 million in Q3 2025, and $184.4 million in Q2 2025.